Suchergebnisse - "Mateos, Maria Victoria"

PubPharm (567)

1

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

enthalten in: Cancer | 2024

von Suvannasankha, A. | Bahlis, N. | Trudel, S. | +17

2

Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Mateos, M. | Weisel, K. | Diels, J. | +7

3

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Einsele, H. | Moreau, P. | Bahlis, N. | +23

4

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

enthalten in: Cancer | 2024

von Nooka, A. | Rodriguez, C. | Mateos, M. | +9

5

Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Oliver-Caldés, A. | Español-Rego, M. | Zabaleta, A. | +37

6

Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma : A Single Institution Experience

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Negrete-Rodríguez, P. | Gallardo-Pérez, M. | Lira-Lara, O. | +9

7

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

8

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

enthalten in: Blood cancer discovery | 2024

von Ghobrial, I. | Gormley, N. | Kumar, S. | +28

9

ANCHOR : melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

enthalten in: Haematologica | 2024

von Ocio, E. | Efebera, Y. | Hájek, R. | +12

10

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma : results from the randomized, open-label, phase III LIGHTHOUSE study

enthalten in: Haematologica | 2024

von Pour, L. | Szarejko, M. | Bila, J. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[57]